

令和7年掲載予定

Annual Trend of Myopia and High Myopia in Children in Japan: a Nationwide Claims Database Study

Takuro Kamei, MD¹; Masahiro Miyake, MD, PhD, MPH¹; Ai Kido, MD, PhD^{1,2}; Saori Wada, MD¹; Shusuke Hiragi, MD, PhD³; Masayuki Hata, MD, PhD¹; Masahiro Akada, MD¹; Koji Niimi, MD⁴; Ken Ogino, MD, PhD⁵; Akio Oishi, MD, PhD⁶; Akihiro Nishida, MD, PhD⁷; Hiroshi Tamura, MD, PhD, ScM^{1,8}; Akitaka Tsujikawa, MD, PhD¹

Affiliations

¹ Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.

² Kyoto Okamoto Memorial Hospital, Kyoto, Japan.

³ Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-Kofukai, Osaka, Japan

⁴ Niimi Eye Institute, Hyogo, Japan.

⁵ Department of Ophthalmology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.

⁶ Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.

⁷ Department of Ophthalmology, Kurashiki Central Hospital, Kurashiki, Okayama, Japan.

⁸ Center for Innovative Research and Education in Data Science, Institute for Liberal Arts and Sciences, Kyoto University, Kyoto, Japan.

Corresponding author:

Masahiro Miyake, M.D., PhD (Kyoto University), MPH (Harvard)

Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 54

Kawahara-cho Syogoin Sakyo-ku Kyoto 606-8507 Japan

Tel.: +81-75-751-3248

Fax: +81-75-752-0933

Email: miyakem@kuhp.kyoto-u.ac.jp

Meeting Presentation: None

Financial Support: This work was supported by JSPS KAKENHI Grant Numbers JP21H03092 and JP21K09740.

Conflict of Interest: No conflicting relationship exists for any author.

Running Head: Annual Trend of Myopia and High Myopia in Children in Japan

Keywords: children's eye health, national database analysis, COVID-19 pandemic impact, epidemiological trends

This article contains additional online-only material. The following should appear online-only: Supplemental Note, Supplemental Tables 2, 3, 4, 5, 6, 7, and 8.

Abbreviations

EMR electronic medical records

ICD International Classification of Diseases

MHLW Japanese Ministry of Health, Labor, and Welfare

NDB National Database of Health Insurance Claims and Specific Health Checkups of Japan

WHO World Health Organization

Abstract

Purpose: To determine the prevalence and annual trend of the number of incident cases of myopia and high myopia in children.

Design: Nationwide, comprehensive claims database study.

Participants: Of 15 million children aged ≤ 14 years, those covered by the universal health insurance were included. The validation study of the claims-based definitions of myopia and high myopia was conducted using 14,654 individuals aged ≤ 14 years recruited from 11 diverse medical facilities.

Methods: This study comprises a national claims database analysis and a multicenter validation study. With permission from the Ministry of Health, Labor and Welfare, data from the National Database of Health Insurance Claims and Specific Health Checkups of Japan, which contains the nationwide health insurance claims data, was assessed. All individuals aged ≤ 14 years were reviewed and children with existing and new onset of myopia or high myopia between January 2011 and December 2020 were identified. A validation study was conducted by reviewing electric medical records.

Main Outcome Measures: Prevalence of myopia as of October 1, 2020 and the annual number of incident cases during 2014–2020.

Results: According to the 2020 population census, there were 14,955,692 children aged ≤ 14 years. Among them, 5,498,764 patients had myopia on October 1, 2020, corresponding to a prevalence of 36.8%. The number of incident cases of myopia was highest at 8 years of age, increasing from 853.3 cases/person-year in 2015 to 910.7 cases/person-year in 2020. The prevalence of high myopia increased with age, peaking at 0.46% among children aged 10–14 years; the number of incident cases annually increased in 5–9 and 10–14-year-olds. In the year 2020, when the COVID-19 pandemic occurred, a discontinuous increase in the number of incident cases of myopia was observed in children aged 8–11 years, not 12–14 years. The overall sensitivity and specificity of the claims-based definition for myopia were 88.5% and 79.2%, respectively, while the corresponding values for high myopia were 41.6% and 99.8%.

Conclusions: This first comprehensive nationwide study revealed the prevalence and annual incidence trends of myopia and high myopia. These findings complement the results of previous high-quality cohort studies,

77 offering a more comprehensive understanding of myopia trends.

78

INTRODUCTION

Myopia, commonly termed as nearsightedness, is a refractive error with significant worldwide prevalence. It is characterized by the ability to clearly see nearby objects while distant objects appear blurred. The World Health Organization (WHO) recognizes uncorrected myopia as a major cause of visual impairment worldwide.¹ Furthermore, the degree of myopia is associated with an increased risk of various ocular and systemic diseases.² Pathological myopia, often observed in highly myopic eyes, is among the leading causes of irreversible visual impairment and blindness among middle-aged and older individuals worldwide.^{3,4}

Recently, there has been a steady increase in the prevalence of myopia among children. Prevalence of myopia (spherical equivalent ≤ -0.5 D) among 15-year-olds was reported to be >80% among East Asians^{5,6} and 50% of the population in Southern California.⁷ Further, the prevalence of high myopia (spherical equivalent ≤ -6 D) among 14–16-year-olds was reportedly 6.69%–11.3% in Asian countries.^{6,8,9} Meticulously planned and executed cohort studies have provided immense value by obtaining detailed individual-level data with strong population representativeness (Table 1). However, the challenge lies in obtaining such large-scale and detailed data at high frequencies, which affects the speed at which data are generated and their real-time nature. In contrast, national claims database studies, such as the present study, although facing challenges in individual data accuracy, maintain population representativeness and high data velocity. This makes them particularly useful for capturing temporal trends. The limitations in individual data accuracy can be mitigated to some extent through appropriate validation studies. Thus, cohort studies and national claims database research each have their strengths and limitations. Combining insights from both approaches can yield a more comprehensive understanding of myopia epidemiology. Nevertheless, although numerous high-quality cohort studies have been conducted, there has been a notable absence of comprehensive national claims database approaches to explore myopia epidemiology. The present study aimed to complement existing high-quality cohort studies by providing annual trends in myopia incidence and prevalence within the pediatric population, utilizing large-scale, claims data. This information is crucial for developing and refining effective management and prevention strategies for myopia.

Therefore, we conducted a nationwide claims database study to evaluate the prevalence and the

number of incident cases of myopia and high myopia. We utilized the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB),¹⁰ which covers > 95% of the claims issued in Japan,¹¹ with permission from the Japanese Ministry of Health, Labor, and Welfare (MHLW). Claims database analysis has a major limitation in that patients who do not visit hospitals cannot be identified. Accordingly, since patients with non-pathological myopia do not generally visit ophthalmology clinics, claims database analysis may be inappropriate for evaluating the epidemiology of myopia. However, in Japan, all 3-year-old infants as well as elementary and junior high school students (i.e., students aged 6–14 years) are required to undergo ophthalmological health checkups under the Maternal and Child Health Act and the School Health and Safety Act, respectively. Moreover, all children with an uncorrected visual acuity < 20/20 are required to visit an ophthalmologist and submit their examination results to their school. Therefore, considering the additional compulsory education in Japan, almost all children with myopia visit ophthalmology clinics and are issued the corresponding claims.

Given these unique conditions, we aimed to conduct the first nationwide claims database study on the prevalence and the number of incident cases of myopia and high myopia. Further, we aimed to evaluate the nationwide impact of the COVID-19 pandemic on the incidence of myopia.

METHODS

We performed a national claims database analysis and validation study of the claims-based definitions of myopia and high myopia using electronic medical records (EMR). This retrospective observational study was approved by the ethics committees of Kyoto University Hospital and Kyoto University Graduate School of Medicine (No. R2405 and R2793) and adhered to the tenets of the Declaration of Helsinki. Informed consent was obtained using an opt-out method.

Database

We analyzed the National Database of Health Insurance Claims and Specific Health Check-ups of Japan (NDB), which is the largest national claims database worldwide and is managed by the Japanese MHLW. Although

previously described,^{12–14} we have summarized details regarding the NDB in the Supplementary Note. This study was conducted during the MHLW-approved study period between August 23, 2021, and February 22, 2022. Upon commencement of the study, the NDB contained > 14 billion claims generated between 2008 and 2021.

Definition and Validation

Diagnoses of myopia and high myopia were determined based on the NDB diagnostic codes for the corresponding refractive status. Table S2 summarizes the correspondence among NDB diagnostic codes, International Classification of Diseases (ICD)-10 diagnostic codes, and refractive status. The validity of these definitions was evaluated in the subsequent validation study.

The validation study was conducted by reviewing EMR data from multiple centers, including university and general hospitals, and private ophthalmology clinics, to avoid institutional bias. Finally, we included 11 institutes, which comprised two university hospitals (Yamanashi University Hospital and Nagasaki University Hospital), two general hospitals (Kurashiki Central Hospital and Japanese Red Cross Wakayama Medical Center), and seven private clinics (Musashi Dream Clinic, Morooka Eye Clinic, Niimi Eye Clinic, Ray Eye Clinic, Nakanishi Eye Clinic, Yamaike Eye Clinic, and Futaba Eye Clinic). We extracted the following patient data from the EMR: date of birth, sex, disease names and their diagnostic codes, date when the disease names were assigned, all refractive indices measured using an autorefractor, and the date of refractive measurement.

The validity of the claims-based definitions was evaluated for participants aged ≤ 14 years who underwent refraction measurement. First, we specified the earliest date of refraction measurement and excluded individuals without diagnostic codes for refractive errors within the same month. Second, we extracted the earliest measured refractive index and the corresponding diagnostic code for refractive error. In our validation study, we performed two distinct analyses. For myopia validation, we dichotomized patients into two groups based on their spherical equivalent: non-myopia ($> -0.5\text{D}$) and myopia ($\leq -0.5\text{D}$). Separately, for high myopia validation, we performed another dichotomization: non-high myopia ($> -6\text{D}$) and high myopia ($\leq -6\text{D}$). This

approach allowed us to properly calculate sensitivity, specificity, positive predictive value, and negative predictive value for both myopia and high myopia diagnoses independently. Additionally, we calculated the aforementioned values with age stratification.

In the case of multiple refraction measurements within a month, the most positive value was used for participants aged ≤ 8 years, and the most negative value for those aged 9–14 years. This approach reflects the common clinical practice in Japan, where cycloplegic refraction is commonly performed in younger children (≤ 8 years), typically resulting in more positive refractive values compared to non-cycloplegic measurements. In older children, where cycloplegia is less commonly used, we selected the more negative value for two reasons: first, the difference between cycloplegic and non-cycloplegic measurements becomes minimal in this age group, and second, some measurements may have been taken over contact lenses, which typically yield more positive values.

Number of Incident Cases and Prevalence of Myopia and High Myopia

After linking all the claims as previously described,^{13,14} we identified the unique IDs of individuals diagnosed with myopia or high myopia between January 1, 2011, and December 31, 2020.

The prevalence was calculated based on individuals diagnosed with myopia at any time until October 1, 2020, when a census was conducted in Japan. The onset of myopia was defined as the date on which the claim containing the myopia diagnostic code was initially issued. Further, we counted the number of incident cases of myopia after 2014, having reserved 3 years from January 1, 2011, to December 31, 2013 as the washout period to ensure that it was the first diagnosis of myopia. In this study, “the number of incident cases” is reported as the number of new cases occurring per 10,000 individuals. A similar approach was used to calculate the prevalence and the number of incident cases of high myopia. Given the very small number of children with high myopia, they were evaluated as a group at 5-year intervals in accordance with Japanese regulations.

The 2020 population census, which was used to calculate the prevalence, and the annual estimates between 2014 and 2020, were provided by the Japanese Ministry of Internal Affairs and Communications; they were used to define the entire population and each subgroup population (available at

<https://www.stat.go.jp/english/data/index.html>, accessed April 24, 2023).

Impact of the COVID-19 Pandemic

In Japan, the first case and outbreak of COVID-19 were confirmed in January and February 2020, respectively. Following the second outbreak in mid-March 2020, the Government of Japan declared a state of emergency on April 7, 2020. The third peak occurred at the beginning of August 2020.¹⁵ Accordingly, the lifestyles of Japanese children changed dramatically, including extensive online schooling, less time spent outdoors, and increased screen time. Therefore, we compared the number of incident cases of myopia between 2019 (pre-pandemic) and 2020 (post-pandemic).

Statistical Analysis

Values are presented as 95% confidence intervals where applicable. All analyses were performed using the R statistical software (R Foundation for Statistical Computing, Vienna, Austria). URL: <https://www.R-project.org/>. Because the target of the current study was not a sampling dataset but a population itself, we did not need for statistical comparison.

RESULTS

Validation Study

The validation study included 14,654 individuals aged ≤ 14 years. Patient characteristics are summarized in Table S3. There were 7,232 males (49.4%), with a mean age of 7.90 ± 3.57 years (mean $\pm$ standard deviation) and a mean refractive index of -0.68 ± 2.76 D. Tables S4 and S5 present the validation study results. The overall sensitivity and specificity of the claims-based diagnosis of myopia were 88.5% and 79.2%, respectively. The sensitivity was $> 80\%$ at ≥ 4 years old. The specificity was greater than 75% at all ages except for 7, 8, and 14 years. When the myopia prevalence was assumed to be 20%, the positive and negative predictive values were 51.6% and 96.5%, respectively. When the myopia prevalence was assumed to be 80%, the positive and negative predictive values were 94.5% and 63.3%, respectively.

The overall sensitivity and specificity of the claims-based diagnosis of high myopia were 41.6% and 99.8%, respectively. Sensitivity tended to increase with age and was approximately 45% for children aged ≥ 10 years. The confidence interval for sensitivity was relatively wide given the small number of children with high myopia. However, the specificity was $> 98\%$ for all ages. Assuming a 0.5% prevalence of high myopia, the positive and negative predictive values were 53.7% and 99.7%, respectively.

Prevalence of Myopia

According to the 2020 population census in Japan, there were 14,955,692 children aged ≤ 14 years. Among them, 5,498,764 patients who were identified as having myopia on October 1, 2020, corresponding to a prevalence of 36.8%. When stratified according to age, the prevalence of myopia increased with age, rising to 83.2% at 14 years old (77.1% in males and 89.6% in females). The most rapid increase in the average myopia prevalence (19.4% to 50.4%) occurred between the ages of 6–9 years. When further stratified by sex, there were no sex differences up to the age of 7 years. However, from the age of ≥ 8 years, the prevalence of myopia among females gradually surpassed that among males (Figure 1 and Table S6).

Number of Incident Cases of Myopia

Figure 2A and Table S7 present the number of age-stratified incident cases of myopia between 2014 and 2020. There were three discontinuous changes in the number of incident cases between the ages of 2 and 3 years, 5 and 6 years, and 11 and 12 years, which corresponded to the beginning of the Health Checkup for Three-Year-Old Infants, elementary school enrollment, and junior high school enrollment, respectively. The number of incident cases of myopia peaked at the age of 8 years after 2015, with an annual increase from 853.3 cases/person-year in 2015 to 910.7 cases/person-year in 2020. There were annual increasing and decreasing trends in the number of incident cases of myopia among children aged 3–8 years and 10–14 years, respectively. Particularly, the largest decrease in the number of incident cases of myopia between 2014 and 2020 occurred among 14-year-old children (743.9 cases/person-year in 2014 to 566.7 cases/person-year in 2020), followed by among 13-year-old children (794.9 cases/person-year in 2014 to 643.5 cases/person-year in 2020).

Figures 2B and C present the comparisons of the number of age- and sex-stratified incident cases of myopia between 2014 and 2019. In both 2014 and 2019, there was a sex difference in the number of incident cases of myopia among children aged ≥ 7 years. In 2014, the number of incident cases of myopia exhibited a bimodal peak for both sexes, with the first and second peaks occurring at the ages of 9 and 12 years, respectively. Another bimodal peak was observed in 2019, with the first and second peaks occurring at the ages of 8 and 12 years, respectively; however, the number of incident cases was lower than that in 2014 (Figure 2B, C, and Table S8).

Prevalence and Number of Incident Cases of High Myopia

Figure 3 shows the comparison of the age- and sex-stratified prevalence, the number of age-stratified incident cases from 2014 to 2020, and the number of age- and sex-stratified incident cases in 2014 and 2019 between high myopia and myopia. The prevalence of high myopia increased with age to 0.46% (0.42% in males and 0.51% in females) in the 10–14 years age group. Although it was similar between males and females in the 5–9 years age group, it was higher among females in the 10–14 years age group.

The number of incident cases of high myopia increased from 2014 to 2020 in both the 5–9 and 10–14 years age groups (1.21 cases/person-year in 2014 to 1.75 cases/person-year in 2020, and 12.4 cases/person-year in 2014 to 13.7 cases/person-year in 2020, respectively). Comparisons of the number of sex-specific incident cases of high myopia and myopia in 2014 and 2019 confirmed the aforementioned trends in both males and females.

Impact of COVID-19 Pandemic on the Number of Incident Cases of Myopia

Figure 2A shows a comparison of the number of age-stratified incident cases of myopia between 2014 and 2020. Within this dataset, we conducted a focused comparison between 2019 and 2020. The number of incident cases of myopia decreased and increased in 2020 compared to 2019 among children aged 3–6 and 8–11 years, respectively. The number of incident cases of high myopia increased from 2019 to 2020 in all age groups (0–4 years, 0.59 cases/person-year in 2019 to 0.68 cases/person-year in 2020; 5–9 years, 1.51 cases/person-year in

2019 to 1.75 cases/person-year in 2020; and 10–14 years, 13.5 cases/person-year in 2019 to 13.7 cases/person-year in 2020).

DISCUSSION

We conducted a nationwide claims database study to assess the epidemiology of myopia in Japan. Further, we clarified the epidemiology of early-onset high myopia, which is often associated with irreversible visual impairment in the middle or later stages of life. Given the public health threat of myopia, this study provides significant implications with respect to public health and elucidation of the epidemiology of myopia since it is the first nationwide claims database study on the prevalence and incidence of myopia and early-onset high myopia.

Myopia is caused by the combined influence of genetic and environmental factors.^{16–19} However, recently, there has been an increase in the prevalence of myopia, especially among young individuals^{20,21} which could be attributed to factors such as prolonged reading of books and the widespread use of digital devices, which increases screen time and reduces time spent outdoors.^{22–24} Since the myopia-related decrease in uncorrected visual acuity affects daily life and academic performance, some Asian countries with a high prevalence of myopia have implemented myopia prevention programs.²⁵ Females are considered to have a higher prevalence of myopia than males; however, the age at which sex differences emerge remains unclear. Our results demonstrated that the myopia prevalence started gradually showing sex differences after the age of 8 years, reaching a difference of > 10% by the age of 14 years. These findings could inform future policymaking and educational campaigns. Further studies are warranted to elucidate the pathogenesis of myopia.

Although several studies have investigated the incidence of myopia among schoolchildren, this is the first nationwide comprehensive study. Table 1 summarizes the literature published over the past two decades. There are considerable variations in the reported prevalence rates, even in Asia. For example, the incidence rates ranged from 31.7% in Taiwan²⁶ to 10.6% in China.²⁷ This discrepancy can be attributed to various factors, including geographical distinctions within the same country (such as urban or rural areas) and even variances

within the same urban locality (such as areas with higher and lower rates of educational advancement). In our study, the number of incident cases of myopia was highest at the age of 8 years, with 868.5 cases per 10,000 person-years, which is consistent with previous reports. Since this was a nationwide comprehensive study, the validity of the results can be considered high.

Consistent with the progressive decrease in the age of myopia onset, the number of incident cases of myopia showed an upward and downward trajectory among children aged < 8 years and ≥ 10 years, respectively (Figure 2A). When stratified by sex, a divergence in the number of incident cases emerged at the age of 7 years, consistent with the sex differences observed in the number of incident cases from the age of ≥ 8 years (Figure 1, Figure 2B). Furthermore, there was a gradual decrease in the age of myopia onset in both sexes, indicating the absence of sex differences in this trend. The current nationwide surveys, when interpreted alongside other epidemiological evidence, provides insights into myopia trends and may serve as one of the monitoring indicators.

Nationwide surveys are beneficial for both policy evaluation and natural experiments. In the present study, the COVID-19 pandemic provided the context for a natural experiment. Generally, a decrease in the number of incident cases was observed in 2020, particularly in preschool children aged 3–6 years. This likely reflects strong reductions in medical visits due to the pandemic rather than an actual decrease in myopia onset. It is presumed that, for young children, there was a stronger tendency to refrain from seeking medical attention for less urgent symptoms during this period. Nevertheless, despite the tendency to avoid healthcare visits, the number of incident cases of myopia exhibited a discontinuous increase in 2020 in children aged 8–11 years, which deviated from the previous annual trend (Figure 2A). This can be attributed to the aforementioned unique conditions of the COVID-19 pandemic (i.e., a reduction in time spent outdoors and an increase in screen time).

High myopia can cause complications and irreversible visual impairment. It is known to increase the risk of glaucoma by 7.3 times,²⁸ retinal detachment by >21.5 times,²⁹ and myopic macular degeneration by 60 times.^{29,30} Complications of high myopia are a significant cause of blindness in developed countries, making it a significant public health issue. Despite the increasing prevalence of high myopia among school-age children,

there have been no nationwide surveys, with several cohort studies being the only reference for its prevalence and incidence rates. The largest study evaluating the prevalence of high myopia in children was the Beijing Childhood Eye Study in 2014, which reported that the prevalence of high myopia was 3.1% among children aged 10–14 years.³¹ Additionally, a survey conducted in Hong Kong between 2005 and 2010 reported a high myopia prevalence of 3.8% among 12-year-olds.³² These findings may reflect the characteristics of urban areas, which may have resulted in higher numbers. In the current study, the prevalence of high myopia was 0.46% among children aged 10–14 years, which was lower than previously reported values. However, despite the relatively low prevalence of high myopia, an increasing trend was observed between 2014 and 2019 for both the 5–9 and 10–14 years age groups, with increases by 1.45 times and 1.10 times, respectively.

Despite the aforementioned strengths of this nationwide claims database study, there are claims database analysis-specific limitations. First, the accuracy of the diagnosis is generally a major limitation. To address this issue, we conducted a validation study covering various regions and institutional scales. The validation study revealed good diagnostic accuracy (Table S4), indicating the reliability of our findings. Second, claims database analyses cannot account for patients who did not visit the hospital. While Japan's school health system encourages ophthalmic examinations for children with reduced visual acuity, the voluntary nature of compliance means we cannot assume complete coverage of all myopic children. This, combined with variations in examination procedures such as the use of cycloplegic refraction, introduces uncertainty into our prevalence estimates. Moreover, caution is warranted when interpreting data from the pandemic period. This is because changes in healthcare-seeking behavior may have influenced the results. Third, While Japan's universal health insurance system provides standardized coverage and predictable costs nationwide, we acknowledge that economic factors may still influence healthcare-seeking behavior as well. Finally, although the NDB serves as a comprehensive administrative database encompassing most medical care services across the entire Japanese population, it does not incorporate medical care expenses covered by social welfare programs or industrial accident compensation insurance. Consequently, we may have overlooked some myopia cases. Nevertheless, given the infrequency of such cases, we posit that their impact on the overall findings is minimal.

In conclusion, this is the first comprehensive nationwide claims database study on myopia and high

myopia evaluating their prevalence and the number of incident cases. Since myopia and high myopia are public health threats, understanding their epidemiology is of great importance. The current study offers valuable information for future myopia prevention strategies and policy-making in various countries, particularly in Asia.

Acknowledgements

TK, MM, AK, SW, and HT conceptualized and designed the study. TK extracted the data and conducted the analyses. TK and MM did the literature search and drafted the manuscript. All authors contributed to the interpretation of the findings and subsequent edits of the manuscript. TK, MM, AK, SW, and HT had full access to the data, and all authors had final responsibility for the decision to submit for publication.

References

- 1 Resnikoff S, Pascolini D, Mariotti SP, Pokharel GP. Global magnitude of visual impairment caused by uncorrected refractive errors in 2004. *Bull World Health Organ* 2008;86:63–70.
- 2 Tideman JWL, Snabel MCC, Tedja MS, et al. Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia. *JAMA Ophthalmol* 2016;134:1355–63.
- 3 Klaver CC, Wolfs RC, Vingerling JR, Hofman A, de Jong PT. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. *Arch Ophthalmol* 1998;116:653–8.
- 4 Cotter SA, Varma R, Ying-Lai M, Azen SP, Klein R. Causes of Low Vision and Blindness in Adult Latinos. The Los Angeles Latino Eye Study. *Ophthalmology* 2006;113:1574–82.
- 5 Rudnicka AR, Kapetanakis VV, Wathern AK, et al. Global variations and time trends in the prevalence of childhood myopia, a systematic review and quantitative meta-analysis: Implications for aetiology and early prevention. *Br J Ophthalmol* 2016;100:882–90.
- 6 Yotsukura E, Torii H, Inokuchi M, et al. Current prevalence of myopia and association of myopia with environmental factors among schoolchildren in Japan. *JAMA Ophthalmol* 2019;137:1233–9.
- 7 Theophanous C, Modjtahedi BS, Batech M, Marlin DS, Luong TQ, Fong DS. Myopia prevalence and risk factors in children. *Clin Ophthalmol* 2018;12:1581–7.
- 8 Li Y, Liu J, Qi P. The increasing prevalence of myopia in junior high school students in the Haidian District of Beijing, China: A 10-year population-based survey. *BMC Ophthalmol* 2017;17:88.
- 9 Samarawickrama C, Mitchell P, Tong L, et al. Myopia-related optic disc and retinal changes in adolescent children from Singapore. *Ophthalmology* 2011;118:2050–7.
- 10 Hirose N, Ishimaru M, Morita K, Yasunaga H. A review of studies using the Japanese National Database of Health Insurance Claims and Specific Health Checkups. *Ann Clin Epidemiol* 2020;2:13–26.
- 11 Sugihara T, Yasunaga H, Matsui H, Kamei J, Fujimura T, Kume H. Regional clinical practice variation in urology: Usage example of the Open Data of the National Database of Health Insurance Claims and Specific Health Checkups of Japan. *Int J Urol* 2019;26:303–5.
- 12 Wada S, Miyake M, Kido A, et al. Epidemiology of angioid streaks and pseudoxanthoma elasticum

376 (2011–2020): A nationwide population-based cohort study. *Ophthalmol Sci* 2023;4:100370.

377 13 Kido A, Miyake M, Tamura H, et al. Incidence and clinical practice of exudative age-related macular
378 degeneration: A nationwide population-based cohort study. *Ophthalmol Sci* 2022;2:100125.

379 14 Kido A, Miyake M, Tamura H, et al. Incidence of central serous chorioretinopathy (2011–2018): A
380 nationwide population-based cohort study of Japan. *Br J Ophthalmol* 2022;106:1748–1753.

381 15 Karako K, Song P, Chen Y, Tang W, Kokudo N. Overview of the characteristics of and responses to
382 the three waves of COVID-19 in Japan during 2020–2021. *Biosci Trends* 2021;15:1–8.

383 16 Miyake M, Yamashiro K, Tabara Y, et al. Identification of myopia-associated WNT7B polymorphisms
384 provides insights into the mechanism underlying the development of myopia. *Nat Commun* 2015;6:6689.

385 17 Fan Q, Verhoeven VJM, Wojciechowski R, et al. Meta-analysis of gene-environment-wide association
386 scans accounting for education level identifies additional loci for refractive error. *Nat Commun* 2016;7:11008.

387 18 Hysi PG, Choquet H, Khawaja AP, et al. Meta-analysis of 542,934 subjects of European ancestry
388 identifies new genes and mechanisms predisposing to refractive error and myopia. *Nat Genet* 2020;52:401–7.

389 19 Nakao SY, Miyake M, Hosoda Y, et al. Myopia prevalence and ocular biometry features in a general
390 Japanese population: The Nagahama Study. *Ophthalmology* 2021;128:522–31.

391 20 Dolgin E. The myopia boom. *Nature* 2015;519:276–8.

392 21 Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and
393 temporal trends from 2000 through 2050. *Ophthalmology* 2016;123:1036–42.

394 22 Sherwin JC, Reacher MH, Keogh RH, Khawaja AP, Mackey DA, Foster PJ. The association between
395 time spent outdoors and myopia in children and adolescents: a systematic review and meta-analysis.
396 *Ophthalmology* 2012;119:2141–51.

397 23 He M, Xiang F, Zeng Y, et al. Effect of time spent outdoors at school on the development of myopia
398 among children in China a randomized clinical trial. *JAMA* 2015;314:1142–8.

399 24 Foreman J, Salim AT, Praveen A, et al. Association between digital smart device use and myopia: a
400 systematic review and meta-analysis. *Lancet Digit Health* 2021;3:e806–18.

401 25 Wu PC, Chen CT, Chang LC, et al. Increased time outdoors is followed by reversal of the long-term

402 trend to reduced visual acuity in Taiwan primary school students. *Ophthalmology* 2020;127:1462–9.

403 26 Tsai DC, Fang SY, Huang N, et al. Myopia development among young schoolchildren: The myopia
404 investigation study in Taipei. *Invest Ophthalmol Vis Sci* 2016;57:6852–60.

405 27 Zhou WJ, Zhang YY, Li H, et al. Five-year progression of refractive errors and incidence of myopia
406 in school-aged children in Western China. *J Epidemiol* 2016;26:386–95.

407 28 Wang YX, Yang H, Wei CC, Xu L, Wei W Bin, Jonas JB. High myopia as risk factor for the 10-year
408 incidence of open-angle glaucoma in the Beijing Eye Study. *Br J Ophthalmol* 2023;107:935–40.

409 29 Flitcroft DI. The complex interactions of retinal, optical and environmental factors in myopia
410 aetiology. *Prog Retin Eye Res* 2012;31:622–60.

411 30 Vongphanit J, Mitchell P, Wang JJ. Prevalence and progression of myopic retinopathy in an older
412 population. *Ophthalmology* 2002;109:704–11.

413 31 You QS, Wu LJ, Duan JL, et al. Prevalence of myopia in school children in greater Beijing: The
414 Beijing Childhood Eye Study. *Acta Ophthalmol* 2014;92:e398–406.

415 32 Lam CSY, Lam CH, Cheng SCK, Chan LYL. Prevalence of myopia among Hong Kong Chinese
416 schoolchildren: Changes over two decades. *Ophthalmic and Physiol Opt* 2012;32:17–24.

417 33 Tideman JWL, Polling JR, Jaddoe VWV, Vingerling JR, Klaver CCW. Environmental risk factors can
418 reduce axial length elongation and myopia incidence in 6- to 9-year-old children. *Ophthalmology* 2019;126:127-
419 136.

420 34 McCullough SJ, O'Donoghue L, Saunders KJ. Six year refractive change among white children and
421 young adults: Evidence for significant increase in myopia among white UK children. *PLoS One*
422 2016;11:e0146332.

423 35 French AN, Morgan IG, Burlutsky G, Mitchell P, Rose KA. Prevalence and 5- to 6-year incidence and
424 progression of myopia and hyperopia in Australian schoolchildren. *Ophthalmology* 2013;120:1482-1491.

425 36 Zhang X, Cheung SSL, Chan HN, et al. Myopia incidence and lifestyle changes among school
426 children during the COVID-19 pandemic: a population-based prospective study. *Br J Ophthalmol*
427 2021;106:1772-1778.

428 37 Ku PW, Steptoe A, Lai YJ, et al. The associations between near visual activity and incident myopia in
429 children: A nationwide 4-year follow-up study. *Ophthalmology* 2019;126:214-220.

430 38 Lin Z, Vasudevan B, Gao T, Zhou H, Ciuffreda KJ, Liang Y. Refractive change and incidence of
431 myopia among rural Chinese children: The Handan Offspring Myopia Study. *Br J Ophthalmol* 2022;106:628-
432 632.

433 39 Ma Y, Zou H, Lin S, et al. Cohort study with 4-year follow-up of myopia and refractive parameters in
434 primary schoolchildren in Baoshan District, Shanghai. *Clin Exp Ophthalmol* 2018;46:861-872.

435 40 Wang SK, Guo Y, Liao C, et al. Incidence of and factors associated with myopia and high myopia in
436 Chinese children, based on refraction without cycloplegia. *JAMA Ophthalmol* 2018;136:1017-1024.

437 41 Li SM, Wei S, Atchison DA, et al. Annual incidences and progressions of myopia and high myopia in
438 Chinese schoolchildren based on a 5-year cohort study. *Invest Ophthalmol Vis Sci* 2022;63:8.

439 42 Wong YL, Yuan Y, Su B, et al. Prediction of myopia onset with refractive error measured using non-
440 cycloplegic subjective refraction: The WEPrOM Study. *BMJ Open Ophthalmol* 2021;6:e000628.

441 43 Li L, Zhong H, Li J, Li CR, Pan CW. Incidence of myopia and biometric characteristics of premyopic
442 eyes among Chinese children and adolescents. *BMC Ophthalmol* 2018;18:178.
443

FIGURE LEGENDS

FIGURE 1. Prevalence of myopia in Japan stratified by age and sex in 2020.

The prevalence increased with age from 19.4% at 6 years to 83.2% at 14 years. A rapid surge in prevalence was observed between the ages of 6–9 years, increasing from 19.4% to 50.4%. Although there were no sex differences in the prevalence up to the age of 7 years, the prevalence among females exceeded that among males from the age of 8 years onwards.

FIGURE 2. Number of age- and-year-stratified incident cases of myopia from 2014 to 2020 (A); Number of age-and sex-stratified incident cases of myopia in 2014 (B) and 2019 (C).

A. Three discontinuous changes corresponded to the beginning of Health Checkup for Three-Year-Old Infants, elementary school enrollment, and junior high school enrollment, respectively. There was an annual increasing and decreasing trend of the number of incident cases of myopia among children aged 3–8 and 10–14 years, respectively. Particularly, the largest decrease in the number of incident cases of myopia from 2014 to 2020 was observed in children aged 14 years. A decrease and increase in the number of incident cases in 2020 compared with that in 2019 was observed in children aged 3–6 and 8–11 years, respectively.

* Elementary school enrollment

† Junior high school enrollment

B, C. In both 2014 and 2019, there were sex differences in the number of incident cases among children aged $\geq$ 7 years. A bimodal pattern of the number of incident cases was observed in both years: in 2014 (B), peaks occurred at ages 9 and 12, while in 2019 (C), peaks occurred at ages 8 and 12, with the peak in 2019 showing a lower rate than that in 2014.

FIGURE 3. For both high myopia (A-D) and myopia (E-H): Age- and sex-stratified prevalence in 2020 (A, E); Number of age-stratified incident cases from 2014 to 2020 (B, F); Number of age- and sex-stratified incident cases in 2014 (C, G) and 2019 (D, H).

The prevalence of high myopia increased with age and tended to increase in females with increasing age (A), which was similar to the trend observed for myopia (E). The number of incident cases of high myopia increased from 2014 to 2020 in both the 5–9 and 10–14 years age groups (B). Contrastingly, the number of incident cases of myopia showed an increasing and decreasing trend for ages 5–9 and 10–14 years, respectively (F). Comparing the number of sex-specific incident cases of high myopia and myopia in 2014 and 2019 revealed that the aforementioned trends were observed in both males and females (C, D, G, H).

Figure1




Figure2




Figure3




Table 1. Summary of previous cohort studies reporting the incidence of myopia in children since 2003

Study Design	Location	Cycloplegia	Starting Year	Age at Baseline (y)	Number of Participants at Baseline	Follow-Up Period	Annual Incidence	Study		
								Author	Journal	Published Year
Population-based	Netherlands	Yes	2008 *	6	6,690	3 years	3.5% ‡	Tideman et al. ³³	<i>Ophthalmology</i>	2019
	United Kingdom	Yes	2006	6	399	6 years	2.2%	McCullough et al. ³⁴	<i>PLoS One</i>	2016
				12	669		0.7%			
	Australia	Yes	2003	6 † 12 †	1,765 2,353	5–6 years	2.2% 4.1%	French et al. ³⁵	<i>Ophthalmology</i>	2013
	Hong Kong	Yes	2015	6 to 8	1,431	3 years	11.6%	Zhang et al. ³⁶	<i>Br J Ophthalmol</i>	2021
			2019	6 to 8	923	8 months	29.7%			
	Taiwan	No	2009	7 to 12	1,958	4 years	6.9% ‡	Ku et al. ³⁷	<i>Ophthalmology</i>	2019
		Yes	2013	7 †	11,590	1 years	31.7%	Tsai et al. ²⁶	<i>Invest Ophthalmol Vis Sci</i>	2016
	mainland	Yes	2006	6 to 15	3,070	5 years	10.6%	Zhou et al. ²⁷	<i>J Epidemiol</i>	2016
China	Yes	2010	6 to 17	630	3–4 years	6.3%	Lin et al. ³⁸	<i>Br J Ophthalmol</i>	2022	
School-based	mainland China	Yes	2010	6 to 8 †	1,856	2 years	18.1% ‡	Ma et al. ³⁹	<i>Clin Exp Ophthalmol</i>	2018
		No	2010	6 †	1,975	5 years	19.1–30.2%	Wang et al. ⁴⁰	<i>JAMA Ophthalmol</i>	2018
				12†	2,670	2 years	24.8–29.1%			
		Yes	2012	6 to 11 †	2,835	5 years	7.8–25.3%	Li et al. ⁴¹	<i>Invest Ophthalmol Vis Sci</i>	2022
		No	2014	6 to 10	1,103	2 years	13.8% ‡	Wong et al. ⁴²	<i>BMJ Open Ophthalmol</i>	2021
		Yes	2016	6 † 12 †	2,432 2,346	1 years	33.6% 54.0%	Li et al. ⁴³	<i>BMC Ophthalmol</i>	2018

* Inferred from the description in the paper.

† Converted grades into ages.

‡ Calculated by dividing the cumulative incidence by the follow-up period.

Supplementary Note

National Database of Health Insurance Claims and Specific Health Check-ups of Japan (NDB)

Japan provides universal health coverage¹ and covers > 95% of all medical care claims for the entire Japanese population of > 127 million people. The data stored in the NDB are anonymized to protect personal information; however, a unique identification is assigned to identify individual patients. The data are made available for academic use through several options and have yielded several significant reports; an onsite option was used in this study. With the approval of the Japanese Ministry of Health, Labor, and Welfare (MHLW), we accessed the database via the NDB Onsite Research Center, Kyoto, which is one of the only two centers with onsite remote access to the complete NDB dataset. This study was conducted during the authorized research period between August 23, 2021, and February 22, 2022. The NDB data include coded information regarding drugs and procedures for both outpatients and inpatients as well as diagnosed diseases, which are coded according to the International Classification of Diseases, Tenth Revision (ICD-10). Furthermore, this information was coded according to the Japanese claim codes: NDB diagnostic codes, NDB drug codes, and NDB procedure codes. At study commencement, data for > 14 billion claims generated between 2008 and 2021 were available. Detailed information regarding the NDB is available in other publications.

References

- 1 Abe S. Japan's strategy for global health diplomacy: Why it matters. *The Lancet* 2013;382:915–916.

Supplemental Table 2. Correspondence Table of Codes Used in the Current Study.

A. Diagnostic Codes for the Definition of Myopia		
NDB code	Disease	ICD-10 code
3671002	High Myopia	H521
3671004	Myopia	H521
3671005	Mild Myopia	H521
3671010	Progressive Myopia	H521
3671011	Moderate Myopia	H521
3671012	Refractive Myopia	H521
3671015	School Myopia	H521
3672003	Myopic Astigmatism	H522
8833933	Extreme Myopia	H521
B. Diagnostic Codes for the Definition of High Myopia.		
NDB code	Disease	ICD-10 code
3671002	High Myopia	H521
8833933	Extreme Myopia	H521

Supplemental Table 3. Patient Demographics of the Validation Study.

Characteristics	Value
Number	14654
Sex (male/female)	7232 (49.4%) / 7422 (50.6%)
Age, mean (SD)	7.90 (3.57)
Spherical equivalent (D), mean (SD)	−0.68 (2.76)

D: diopter

Supplemental Table 4. Validation of “Myopia”.

Age	Sensitivity	Specificity	Positive Predictive Value	Negative Predictive Value	Number
0	–	–	–	–	0
1	0.72 (0.59–0.85)	0.79 (0.72–0.87)	0.56 (0.43–0.69)	0.88 (0.82–0.95)	158
2	0.71 (0.60–0.82)	0.83 (0.78–0.88)	0.52 (0.42–0.63)	0.91 (0.88–0.95)	311
3	0.58 (0.52–0.65)	0.89 (0.88–0.91)	0.47 (0.41–0.53)	0.93 (0.92–0.94)	1631
4	0.77 (0.71–0.83)	0.84 (0.82–0.86)	0.47 (0.41–0.53)	0.95 (0.94–0.97)	1107
5	0.82 (0.77–0.87)	0.82 (0.80–0.84)	0.51 (0.45–0.56)	0.95 (0.94–0.97)	1143
6	0.89 (0.85–0.92)	0.78 (0.76–0.81)	0.54 (0.49–0.58)	0.96 (0.95–0.97)	1392
7	0.92 (0.90–0.95)	0.70 (0.67–0.74)	0.68 (0.64–0.71)	0.93 (0.91–0.95)	1275
8	0.95 (0.93–0.97)	0.63 (0.59–0.67)	0.69 (0.66–0.73)	0.93 (0.91–0.96)	1281
9	0.86 (0.84–0.88)	0.80 (0.75–0.84)	0.91 (0.90–0.93)	0.69 (0.64–0.74)	1161
10	0.88 (0.86–0.90)	0.76 (0.71–0.81)	0.91 (0.90–0.93)	0.68 (0.63–0.73)	1128
11	0.90 (0.88–0.92)	0.75 (0.68–0.81)	0.94 (0.92–0.96)	0.63 (0.57–0.70)	992
12	0.91 (0.89–0.93)	0.79 (0.73–0.85)	0.96 (0.95–0.97)	0.61 (0.55–0.68)	1083
13	0.91 (0.89–0.93)	0.76 (0.69–0.82)	0.95 (0.94–0.96)	0.62 (0.55–0.68)	1029
14	0.93 (0.91–0.94)	0.66 (0.57–0.75)	0.95 (0.94–0.97)	0.55 (0.47–0.63)	963
Total	0.89 (0.88–0.89)	0.79 (0.78–0.80)	0.81 (0.80–0.81)	0.88 (0.87–0.88)	14654

Supplemental Table 5. Validation of “High Myopia”.

Age	Sensitivity	Specificity	Positive Predictive Value	Negative Predictive Value	Number
0–4	0.41 (0.23–0.59)	1.00 (1.00–1.00)	0.57 (0.36–0.78)	0.99 (0.99–1.00)	3207
5–9	0.33 (0.22–0.45)	1.00 (1.00–1.00)	0.62 (0.45–0.78)	0.99 (0.99–1.00)	6252
10	0.46 (0.31–0.62)	1.00 (1.00–1.00)	1.00 (1.00–1.00)	0.98 (0.97–0.99)	1128
11	0.39 (0.27–0.51)	1.00 (1.00–1.00)	1.00 (1.00–1.00)	0.96 (0.95–0.97)	992
12	0.46 (0.37–0.56)	1.00 (1.00–1.00)	0.98 (0.94–1.02)	0.95 (0.93–0.96)	1083
13	0.41 (0.32–0.51)	1.00 (0.99–1.00)	0.95 (0.89–1.02)	0.94 (0.92–0.95)	1029
14	0.42 (0.34–0.50)	1.00 (1.00–1.00)	1.00 (1.00–1.00)	0.90 (0.88–0.92)	963
Total	0.42 (0.37–0.46)	1.00 (1.00–1.00)	0.90 (0.87–0.94)	0.98 (0.98–0.98)	14654

Supplemental Table 6. Prevalence of Myopia.

	Male			Female			Overall		
Age	Patients	Population	Prevalence (%)	Patients	Population	Prevalence (%)	Patients	Population	Prevalence (%)
0	273	425174	0.06	263	406650	0.06	536	831824	0.06
1	1795	443318	0.40	1474	423207	0.35	3269	866525	0.38
2	4267	465785	0.92	3793	444220	0.85	8060	910005	0.89
3	16023	477647	3.35	14743	456416	3.23	30766	934063	3.29
4	39665	499265	7.94	35534	474400	7.49	75199	973665	7.72
5	63047	511421	12.33	56810	487243	11.66	119857	998664	12.00
6	100964	511271	19.75	92457	485305	19.05	193421	996576	19.41
7	153554	522070	29.41	146274	498587	29.34	299828	1020657	29.38
8	209705	524058	40.02	207484	500267	41.47	417189	1024325	40.73
9	260379	537831	48.41	268064	511040	52.45	528443	1048871	50.38
10	306959	542356	56.60	323294	515380	62.73	630253	1057736	59.59
11	335288	545009	61.52	355989	518176	68.70	691277	1063185	65.02
12	377892	554827	68.11	402744	528286	76.24	780636	1083113	72.07
13	400085	552460	72.42	430594	524919	82.03	830679	1077379	77.10
14	421937	547479	77.07	467414	521625	89.61	889351	1069104	83.19
0–14	2691833	7659971	35.14	2806931	7295721	38.47	5498764	14955692	36.77

Supplemental Table 7. The Number of Incident Cases of Myopia.

Age	Year						
	2014	2015	2016	2017	2018	2019	2020
0	9.62	9.77	9.87	11.68	12.47	14.53	14.09
1	17.28	18.38	19.27	20.72	23.16	24.79	24.70
2	43.34	44.86	45.37	47.63	46.02	47.39	45.40
3	276.82	293.17	292.07	317.94	333.39	316.52	275.83
4	297.53	306.21	304.64	320.34	329.68	323.93	272.83
5	370.18	370.53	374.11	389.00	405.83	402.59	350.85
6	663.35	691.59	713.81	732.37	760.75	767.71	719.73
7	764.99	777.69	815.35	823.43	858.07	856.70	856.61
8	833.47	853.27	858.79	863.41	884.00	877.77	910.65
9	849.96	845.64	854.88	833.71	852.44	829.63	864.20
10	801.07	805.46	791.49	771.39	759.51	749.17	784.98
11	741.31	739.74	727.57	693.06	686.00	660.68	700.68
12	825.70	803.96	787.13	750.99	710.29	693.53	690.14
13	794.91	796.25	757.71	723.14	686.82	656.66	643.50
14	743.90	732.28	701.27	658.29	608.48	579.88	566.69

*10,000 person–years

Supplemental Table 8. The Number of Incident Cases of Myopia in 2014 and 2019.

Age	Year			
	2014		2019	
	Male	Female	Male	Female
0	10.11	9.09	15.52	13.49
1	17.22	17.34	25.64	23.90
2	44.10	42.54	47.95	46.80
3	284.54	268.67	324.59	308.01
4	307.47	287.68	333.63	314.51
5	375.45	364.67	410.40	394.41
6	656.45	670.57	762.92	772.71
7	725.48	806.38	827.58	887.22
8	777.13	894.13	822.05	936.33
9	780.07	923.23	780.32	883.17
10	726.58	880.52	690.68	810.72
11	672.96	813.30	595.61	727.71
12	746.72	908.61	630.89	759.27
13	711.17	882.76	589.52	727.15
14	667.09	824.99	529.23	633.05

*10,000 person–years